Amneal Pharmaceuticals, Inc. AMRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s EPS (diluted)?
- Amneal Pharmaceuticals, Inc. (AMRX) reported EPS (diluted) of $0.19 in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s EPS (diluted) increased by 375.0% year-over-year, from $0.04 to $0.19.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s EPS (diluted)?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s EPS (diluted) has grown at a -35.6% compound annual growth rate (CAGR), from -$0.86 to $0.23.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.